www.feizichem.com     Shijiazhuang FeiZi Chemical Technology Co., Ltd

Recently, the United States announced tariffs of up to 200% on imported pharmaceuticals, set to take effect in a year and a half, with the aim of bringing manufacturing back to the U.S. Major companies like Pfizer and Eli Lilly, which have factories in Ireland—where pharmaceutical exports account for 38% of the country’s total exports—have already announced plans to invest in U.S. manufacturing facilities over the next five years.

Challenges for China:
Multinational corporations are accelerating the relocation of production capacity to Southeast Asia, with Vietnam seeing a more than 300% increase in orders for textiles and electronics previously handled by China.

Cost Dilemma:
Manufacturing wages in China have reached 30% of U.S. levels, with the labor cost advantage continuing to weaken.

Three Breakthroughs for "Smart Manufacturing" in China:

Technological Advancement: Enhance competitiveness through innovation.

Market Diversification: For export-oriented businesses, explore new regions and markets.

Intelligent Transformation: Accelerate smart production to reduce costs.

Corporate Action Declaration:
We will seize the window of opportunity in the global supply chain restructuring, increase investment in R&D, and enhance risk resilience through the development of digital supply chains.

Our  products:

Phenyl-(2-pyridyl)acetamide CAS: 7251-52-7

4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butanedione     CAS: 720-94-5

4-tert-Butylcatechol CAS: 98-29-3

5,6-Diamino-1,3-dihydro-2H-benzoimidazol-2-one      CAS: 55621-49-3

(R)-1-[(4-Chlorophenyl)phenylmethyl]piperazine      CAS: 300543-56-0